November 19, 2020
Kyowa Kirin said on November 18 that its partner Sandoz obtained approval for their biosimilar version of the cancer agent Rituxan (rituximab) in Japan for an additional indication and dosage for the treatment of acquired thrombotic thrombocytopenic purpura. Kyowa Kirin...read more